Jun 18
Current report
8-K
Director or officer change, or executive pay, Shareholder vote results
TXMD · TherapeuticsMD, Inc. · Documents
$1.75
-0.07 (-3.85%)
At close · Nov 5
View the 10-Q filed Aug 11, 2026
Return incl. dividend (before tax)
Q2 2022 earnings call transcript
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“The potential impact of these factors in conjunction with the uncertainty of the capital markets raises substantial doubt about our ability to continue as a going concern for the next twelve months from the issuance of these financial statements.”View the 10-Q filed Aug 11, 2026
Customer concentration
— top 3 customers 100% of revenue
3 customers — 100% of revenue (the three and six months ended June 30, 2026)
“For the three and six months ended June 30, 2026, 100% of license revenue related to Mayne Pharma, Theramex and Knight.”
Market Cap
$21.07M
Shares
11.57M
Volume · Nov 5
7362
Avg daily vol (3M)
23.41K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
2020
Jun 1
Current report
8-K
Director or officer change, or executive pay, Regulation FD disclosure
May 15
Current report
8-K
Events of May 14
Ended a material agreement, Other events
May 13
Current report
8-K
Regulation FD disclosure
May 6
Earnings call
Q1 2020 earnings call
May 6
Current report
8-K
Financial results, Regulation FD disclosure
May 6
Quarterly report
10-Q
FY2020 Q1, ended Mar 31
Quarterly report for FY2020 Q1
Revenue $12.25M
▲ 210.4%
Net loss $56.85M
May 4
Proxy statement
DEF 14A
Meeting Jun 18, 2020
Proxy statement
May 4
Proxy statement
DEFA14A
Proxy statement
May 1
Current report
8-K
Events of Apr 27
Entered into a material agreement, New debt or off-balance-sheet obligation
Apr 29
Annual report
10-K/A
Ended Dec 31
Annual report for the period ended Dec 31, 2019
Apr 22
Current report
8-K
Events of Apr 16
Director or officer change, or executive pay, Regulation FD disclosure, Other events
Apr 13
Proxy statement
PRE 14A
Meeting Jun 18, 2020
Proxy statement
Mar 26
Current report
8-K
Regulation FD disclosure, Other events
Mar 24
Current report
8-K
Events of Mar 20
Director or officer change, or executive pay, Regulation FD disclosure
Mar 3
Current report
8-K
Regulation FD disclosure
Feb 24
Annual report
10-K
FY2019, ended Dec 31
Annual report for FY2019
Revenue $49.65M
▲ 208.4%
Net loss $176.14M
Feb 20
Current report
8-K
Events of Feb 18
Financial results, New debt or off-balance-sheet obligation, Regulation FD disclosure
Jan 14
Current report
8-K
Financial results, Regulation FD disclosure
Showing 151–169 of 169 documents